Effect on cardiovascular outcome of sodium-glucose co-transporter-2 (SGLT2) inhibitors among cancer patients treated with anthracycline: a systematic review and meta-analysis
5
Issued Date
2025-01-01
Resource Type
eISSN
17546605
Scopus ID
2-s2.0-85218425985
Journal Title
ecancermedicalscience
Volume
19
Rights Holder(s)
SCOPUS
Bibliographic Citation
ecancermedicalscience Vol.19 (2025)
Suggested Citation
Wannaphut C., Wattanachayakul P., Saowapa S., Ponvilawan B., Tanariyakul M., Kewcharoen J., Yingchoncharoen P., Suenghataiphorn T., Aiumtrakul N., Acoba J. Effect on cardiovascular outcome of sodium-glucose co-transporter-2 (SGLT2) inhibitors among cancer patients treated with anthracycline: a systematic review and meta-analysis. ecancermedicalscience Vol.19 (2025). doi:10.3332/ecancer.2025.1844 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/105484
Title
Effect on cardiovascular outcome of sodium-glucose co-transporter-2 (SGLT2) inhibitors among cancer patients treated with anthracycline: a systematic review and meta-analysis
Corresponding Author(s)
Other Contributor(s)
Abstract
Background/objectives: Sodium-glucose-co-transporter-2 (SGLT2) inhibitors have shown benefit in reducing cardiovascular disease outcomes in diabetes patients. Anthracycline therapy is associated with a risk of cardiomyopathy. However, the impact of SGLT2 inhibitors in the prevention of cardiomyopathy and heart failure in cancer patients undergoing anthracycline treatment remains unclear. Thus, we conducted a systematic review and meta-analysis to explore the effect of the prevention of cardiovascular outcomes in patients with cancer and diabetes who had received anthracycline therapy. Methods: We systematically reviewed Medline and EMBASE databases from inception to January 2024 for studies focusing on cancer patients with a history of anthracycline therapy. Eligible studies had to report relative risk (RR) with 95% confidence intervals (CIs) for the clinical endpoints of mortality outcomes and the risk of heart failure exacerbation, comparing cohorts with and without SGLT2 inhibitor use. Results: Our study included four retrospective cohort studies in the meta-analysis (n = 6,708, 24% received SGLT2). There was significantly lower all-cause mortality in the SGLT2 inhibitors group (pooled RR of 0.52, 95% CI 0.35–0.77, I2 64%). However, there were no differences in the risk of heart failure exacerbation (pooled RR of 0.67, 95% CI 0.39–1.14, I2 17%). Conclusion: Our study found that anthracycline-treated cancer patients using SGLT2 inhibitors experienced lower all-cause mortality compared to the control group. A randomised clinical trial is necessary to further elucidate these findings.